Gothenburg, Sweden, April 27, 2021 - Elicera Therapeutics, a clinical phase cell and gene therapy company that develops immunooncological treatments focusing on CAR T cells and oncolytic viruses, announced today that the company has filed a patent application to protect the development of its drug candidate ELC- 201, a next generation of oncolytic virus.
ELC-201 is the second oncolytic virus in Elicera Therapeutic's product portfolio. It is based on an adenovirus that has been genetically modified in a way that makes the treatment applicable to most cancers and the patent application protects the application of two more genetic modifications in combination that together give the drug candidate three mechanisms of action.
In addition to ELC-201, Elicera is also developing ELC-100, an oncolytic virus developed for the treatment of neuroendocrine tumors. ELC-100 is currently in an ongoing Phase I / II clinical trial.
About Elicera Therapeutics
Elicera is a clinical stage cell and gene therapy company active in the field of immuno-oncology. Based on the leading research by Professor Magnus Essand’s work at Uppsala University, the Company has four drug candidates, two in the field of CAR-T cells and two in the field of oncolytic viruses. Most advanced is ELC-100, an oncolytic virus for NET which is Phase I/II, while ELC-301, an enhanced CAR-T therapy is due to enter Phase I second half of 2022. Elicera has also completed development of a proprietary technology platform called iTANK (immunoTherapies Activated with NAP for efficient Killing) for optimization of any CAR T-cell therapy under development and generation of a second mode of action through activation of CD8+ T-cells against cancer.
For more information, please visit www.elicera.com